About
Basic Data Updated:
9 days agoNatco Pharma Limited is known for its involvement in the development, manufacturing, and marketing of pharmaceutical formulations and APIs, according to its credit ratings report. The company's domestic formulations segment is comprised of products specifically designed for the oncology and specialty pharma segments. In India, Natco Pharma Limited possesses a total of seven manufacturing facilities, which includes five formulations and two APIs facilities. Additionally, the company has a Natco Research Centre located in Hyderabad, dedicated to research and development. The formulation unit situated in Kothur and the API facility at Mekaguda have both been approved by regulatory authorities in various markets, including the US FDA. Furthermore, Natco Pharma Limited has a significant presen... Read More
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Website1222442
- Telephone1222442
- Email Address1222442
- Social Media1222442
| CIN/LLPIN/FCRN | L24230TG1981PLC003201 |
| Company No. | 003201 |
| Stock Symbol | BSE : 524816 NSE : NATCOPHARM |
| Company Classification | Public Limited Indian Non-Government Company |
| Incorporation Date | 19 Sep 1981 |
| Date of AGM | 29 Sep 2023 |
| Date of Balance Sheet | 31 Mar 2023 |
| Listing Status | Listed |
| ROC Code | Roc Hyderabad |
Products or Services related to Natco Pharma Limited
Steroid
Pain Killers
Financials of Natco Pharma Limited
Natco Pharma Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 30.83% increase. The company also saw a substantial improvement in profitability, with a 358.02% increase in profit. The company's net worth Soared by an impressive increase of 12.17%.
Enhance accessibility to Natco Pharma's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
Corporate Structure
Unlock access to Natco Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
People in Natco Pharma Limited
Unlock and access historical data on people associated with Natco Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Executive Team (3)
VN
Venkaiah Nannapaneni
Managing DirectorAppointment Date: 01-Apr-2015
Status: Current
SR
S Rao CFOAppointment Date: 11-Feb-2016
Status: Current
VC
Venkat Chekuri Company SecretaryAppointment Date: 01-Apr-2022
Status: Current
Board Members(9)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 08 Mar 2011 | ₹520.00 Cr | Open |
Others Creation Date: 18 Oct 2016 | ₹50.00 Cr | Satisfied |
Citi Bank N.A. Creation Date: 22 Jun 2015 | ₹12.05 Cr | Satisfied |
Deals i
Gain comprehensive insights into the Deals and Valuation data of Natco Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Natco Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alert
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Related Corporates (Common Directorship)
Mitcon Credentia Trusteeship Services Limited
Active
5 years 5 months Venkateswara Thallapaka is a mutual person
Recent activity within the organization
Director Appointment
Agnihotra Dakshina Murty Chavali was appointed as a Director was appointed as a Director on 23 Apr 2024 & has been associated with this company since 11 days .
23 Apr 2024Director Appointment
Vijayabhaskar Dronadula was appointed as a Director was appointed as a Director on 23 Apr 2024 & has been associated with this company since 11 days .
23 Apr 2024Annual General Meeting
Natco Pharma Limited last Annual general meeting of members was held on 29 Sep 2023 as per latest MCA records.
29 Sep 2023Balance Sheet
Natco Pharma Limited has filed its annual Financial statements for the year ended 31 Mar 2023 with Roc Hyderabad.
31 Mar 2023Charges
A charge with Others of Rs. 520.00 cr registered on 08 Mar 2011 with Charge ID 10271782 was modified on 27 Jun 2019.
27 Jun 2019
Recent News, Updates & Announcement
Natco Pharma to acquire 5 stake in biotech startup Cellogen Therapeutics for 15 cr.The Hindu 17 Jan 2024
- Natco Pharma to set up subsidiary in Indonesia with investment of 3 mn.
Business Standard 20 Apr 2023
- Natco Pharma invests Rs 75 cr in PACE Hospital.
Business Line 04 Nov 2017
- Natcos partner Alvogen gets nod for influenza drug in US.
In December last year Alvogen launched the first generic equivalent to oseltamivir phosphate capsules in the United States.
PTI 03 Nov 2017
- Natco Pharmas Generic Tamiflu Deal Brings in Big Profits in Q3 Shares Soar.
When you sell generic Tamiflu in the US and make bank Natco Pharmas net profit rose to Rs 1948 crore in Q3 thanks to the exclusivity of their generic Tamiflu drug They made a deal with Gilead and Roche and teamed up with Alvogen Inc to challenge patents Tamiflu had US sales of 403 million in 2015 Natcos shares went up while Sensex went down.
Moneycontrol 14 Feb 2017
Frequently asked questions
What is the Incorporation or founding date of Natco Pharma Limited?
